Therapeutic Drug Monitoring During Induction of Anti–Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Drug Monitoring During Induction of Anti–Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Authors
Keywords
-
Journal
INFLAMMATORY BOWEL DISEASES
Volume 23, Issue 9, Pages 1510-1515
Publisher
Oxford University Press (OUP)
Online
2017-08-16
DOI
10.1097/mib.0000000000001231
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High Infliximab Levels are not Associated with a Higher Risk of Infection in IBD Patients
- (2017) Tomer Greener et al. GASTROENTEROLOGY
- A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease
- (2017) Johannan F. Brandse et al. INFLAMMATORY BOWEL DISEASES
- Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience
- (2016) T. Billiet et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis
- (2016) B. Ungar et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2016) Bella Ungar et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
- (2016) Johannan F. Brandse et al. Clinical Gastroenterology and Hepatology
- Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
- (2016) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Efficacy and Safety Profile of Anti–tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn’s Disease: A Network Meta-analysis of Indirect Comparisons
- (2016) Michael Miligkos et al. CLINICAL THERAPEUTICS
- Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohnʼs Disease
- (2016) Ronen Stein et al. INFLAMMATORY BOWEL DISEASES
- Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab
- (2016) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis
- (2016) Iris Detrez et al. Journal of Crohns & Colitis
- Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
- (2016) Omoniyi J. Adedokun et al. Journal of Crohns & Colitis
- Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis
- (2016) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
- (2016) Theodora Bejan-Angoulvant et al. Arthritis & Rheumatology
- Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation
- (2016) Thomas Van Stappen et al. Clinical and Translational Gastroenterology
- A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis
- (2015) Maria Theresa Arias et al. Clinical Gastroenterology and Hepatology
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
- (2015) Henit Yanai et al. Clinical Gastroenterology and Hepatology
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
- (2015) Johannan F. Brandse et al. GASTROENTEROLOGY
- Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial
- (2015) Filip Baert et al. GUT
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
- (2015) Andres J Yarur et al. GUT
- Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD
- (2015) Konstantinos Papamichael et al. INFLAMMATORY BOWEL DISEASES
- Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment
- (2015) Johannan F. Brandse et al. Journal of Crohns & Colitis
- First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
- (2015) Taku Kobayashi et al. JOURNAL OF GASTROENTEROLOGY
- Biologic agents for IBD: practical insights
- (2015) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- A Study Investigating the Association of Dermatological and Infusion Reactions to Infliximab and Infliximab Trough Levels
- (2015) Vivian Wai-Mei Huang et al. Canadian Journal of Gastroenterology and Hepatology
- Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside
- (2014) Diane R. Mould et al. AAPS Journal
- Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis
- (2014) F. Baert et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
- (2014) Filip Baert et al. Clinical Gastroenterology and Hepatology
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease
- (2014) Byron P. Vaughn et al. INFLAMMATORY BOWEL DISEASES
- Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease
- (2014) Namita Singh et al. INFLAMMATORY BOWEL DISEASES
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Optimizing anti-TNF treatments in inflammatory bowel disease
- (2013) Shomron Ben-Horin et al. AUTOIMMUNITY REVIEWS
- A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
- (2013) Fernando S. Velayos et al. Clinical Gastroenterology and Hepatology
- Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
- (2013) Jean–Frédéric Colombel et al. Clinical Gastroenterology and Hepatology
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- Pharmacokinetics of Infliximab in Children with Moderate-to-Severe Ulcerative Colitis
- (2013) Omoniyi J. Adedokun et al. INFLAMMATORY BOWEL DISEASES
- C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease
- (2013) Toshifumi Hibi et al. JOURNAL OF GASTROENTEROLOGY
- Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
- (2012) Martin Bortlik et al. Journal of Crohns & Colitis
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started